November 1, 2017: The National Center for Health Research (NCHR) strongly opposes the FDA’s proposed delay in implementing updated Nutrition Facts and Serving Size labels. They emphasized that postponing these changes hinders Americans’ ability to make informed dietary choices, particularly concerning added sugars and realistic serving sizes, which are crucial for managing health conditions like obesity, diabetes, and heart disease.
Read More »On Health Policy
NCHR Comments on HHS Draft Strategic Plan FY2018-2022
October 26, 2017. The HHS has drafted a strategic plan for implementation over the next several years. We object to language that is non-scientific and themes which weight political rhetoric and ideology over sound scientific principles. Read more of our comments here.
Read More »NCHR Letter to the DC City Council on Artificial Turf
October 26, 2017. It is clear that city officials have assumed artificial turf products are safe because the salespeople told them they were safe. Unfortunately, there is clear scientific evidence that these materials are potentially harmful, and the only question is how harmful are they and how much exposure is likely to be harmful? Our children deserve better.
Read More »NCHR Comments at CDRH’s Voluntary Medical Device Manufacturing and Product Quality Workshop
October 10, 2017. Recalls demonstrate the crucial need for improved medical device quality, and for more clinical testing of such devices before they are put onto the marketplace, as well as improved inspections of manufacturing facilities prior to them going on the market. It’s a positive sign that this pilot program will address at least some of these inspectional issues.
Read More »NCHR Statement on Right To Try Legislation before the House Energy and Commerce Subcommittee on Health
October 3, 2017. We strongly urge this Committee to reject the Right To Try legislation that is currently under consideration, because it would undermine the successful FDA compassionate waiver program already in place to enable patients to have access to experimental drugs for free or at cost.
Read More »